June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Evaluation of Visual Acuity Measurements with Standard Luminance Compared with Low Luminance in Eyes with Geographic Atrophy from Age-related Macular Degeneration
Author Affiliations & Notes
  • Diana V Do
    Ophthalmology, Truhlsen Eye Institute, U of Nebraska, Omaha, NE
  • Neil M Bressler
    Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD
  • Quan Dong Nguyen
    Ophthalmology, Truhlsen Eye Institute, U of Nebraska, Omaha, NE
  • Mostafa Saad Hanout
    Ophthalmology, Truhlsen Eye Institute, U of Nebraska, Omaha, NE
  • Susan B Bressler
    Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD
  • Footnotes
    Commercial Relationships Diana Do, allergan (C), genentech (C), genentech (F), regeneron (C), regeneron (F); Neil Bressler, Bayer (F), Genentech (F), Novartis (F), Regeneron (F); Quan Dong Nguyen, Bayer (C), Genentech (C), Genentech (F), Regeneron (C), Regeneron (F); Mostafa Hanout, None; Susan Bressler, Genentech (F), glaxo smith kline (C), novartis (F), regeneron (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 2821. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Diana V Do, Neil M Bressler, Quan Dong Nguyen, Mostafa Saad Hanout, Susan B Bressler; Evaluation of Visual Acuity Measurements with Standard Luminance Compared with Low Luminance in Eyes with Geographic Atrophy from Age-related Macular Degeneration . Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):2821.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

Prior studies suggest low luminance (LL) best-corrected visual acuity (BCVA) may affect the prognosis of visual acuity loss in eyes with geographic atrophy (GA) due to age-related macular degeneration (AMD). In order to expand our understanding of the contribution made by LL BCVA in the management of eyes with GA, this study compares standard and LL BCVA in such eyes

 
Methods
 

Eligible eyes had the following: (1) BCVA letter score with standard luminance of 18 (approximate Snellen equivalent of 20/400) or greater on a retroilluminated Early Treatment Diabetic Retinopathy Study (ETDRS) chart following a protocol refraction and visual acuity measurement by a certified visual acuity examiner, (2) GA due to AMD with a minimum total diameter of 0.5 disc area within 3000 um of the fovea, and (3) no choroidal neovascularization. Study eyes underwent evaluation with standard and then LL BCVA. LL BCVA was measured by placing a 2.0-log-unit neutral density filter over the trial frame in front of the study eye and having the participant read the normally illuminated ETDRS chart using a different version of the chart. IBM SPSS v19.0 software was used to calculate means, standard deviations, and standard errors.

 
Results
 

27 subjects (53%) were women and 44 (86.3%) were Caucasian. Mean age (+ standard deviation) was 80.5 (+ 7.4) years. At baseline, the mean (+SD) BCVA letter score with standard luminance (approximate Snellen equivalent) was 54.9 (20/80) + 19.5 (+ approximately 4 lines, assuming 5 letters per line). The mean LL BCVA letter score was 34.1 (20/200) + 18.9 (+ approximately 4 lines.). The difference between standard and LL scores averaged 20.9 (±14.1) letters, P<0.001. The mean total area of GA was 10.1 + 9.2 mm2 (3.9 + 3.6 disc areas) on digital color photos.

 
Conclusions
 

In this cohort, the average of the differences between BCVA with standard luminance and LL BCVA was substantial, although there was a wide variability of differences across the pairs of measurements. Additional studies with longitudinal data will be of value to determine the prognostic value of LL BCVA as well as the difference between standard and LL BCVA on the natural course and treatment outcomes in eyes with GA due to AMD.

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×